These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9859750)

  • 21. An approach to cultural adaptation and validation: the Intermittent Claudication Questionnaire.
    Ketenci B; Tuygun AK; Gorur A; Bicer M; Ozay B; Gunay R; Guney MR; Sargin M; Cimen S; Demirtas MM; Yekeler I
    Vasc Med; 2009 May; 14(2):117-22. PubMed ID: 19366817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intermittent claudication].
    Ibsen B
    Ugeskr Laeger; 1992 Aug; 154(35):2377. PubMed ID: 1413156
    [No Abstract]   [Full Text] [Related]  

  • 23. Naftidrofuryl for intermittent claudication: a double-blind controlled trial.
    Ruckley CV; Callam MJ; Ferrington CM; Prescott RJ
    Br Med J; 1978 Mar; 1(6113):622. PubMed ID: 343869
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older adults with intermittent claudication.
    Izquierdo-Porrera AM; Gardner AW; Bradham DD; Montgomery PS; Sorkin JD; Powell CC; Katzel LI
    J Vasc Surg; 2005 Apr; 41(4):625-30. PubMed ID: 15874926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inositol nicotinate in intermittent claudication.
    Practitioner; 1986 Jun; 230(1416):506-9. PubMed ID: 3748967
    [No Abstract]   [Full Text] [Related]  

  • 26. Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989-2008) review.
    Guidon M; McGee H
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):140-54. PubMed ID: 20215969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current EMNID survey on peripheral arterial occlusive disease].
    Krankenpfl J; 2002; 40(7-9):217. PubMed ID: 12514861
    [No Abstract]   [Full Text] [Related]  

  • 28. Risk attitudes to treatment among patients with severe intermittent claudication.
    Letterstål A; Forsberg C; Olofsson P; Wahlberg E
    J Vasc Surg; 2008 May; 47(5):988-94. PubMed ID: 18455642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of including quality of life responses in models to predict walking performance of patients with intermittent claudication.
    Leicht AS; Crowther RG; Muller R; Golledge J
    Eur J Vasc Endovasc Surg; 2011 Apr; 41(4):511-7. PubMed ID: 21247784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life and functional status after revascularization or conservative treatment in patients with intermittent claudication.
    Hedeager Momsen AM; Bach Jensen M; Norager CB; Roerbæk Madsen M; Vestersgaard-Andersen T; Lindholt JS
    Vasc Endovascular Surg; 2011 Feb; 45(2):122-9. PubMed ID: 21278180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Incomplete description of effect data in intermittent claudication].
    Nilsson KA; Cline C
    Lakartidningen; 2010 Sep 1-7; 107(35):2021. PubMed ID: 21043188
    [No Abstract]   [Full Text] [Related]  

  • 32. Adjunctive pharmacotherapies for intermittent claudication--NICE guidance.
    Shalhoub J; Davies AH
    Heart; 2012 Feb; 98(3):244-5. PubMed ID: 21993771
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of claudication and its treatment on quality of life.
    Spronk S; White JV; Bosch JL; Hunink MG
    Semin Vasc Surg; 2007 Mar; 20(1):3-9. PubMed ID: 17386358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intermittent claudication as chronic illness].
    Hartmann F
    Vasa Suppl; 1991; 32():605-14. PubMed ID: 1771585
    [No Abstract]   [Full Text] [Related]  

  • 35. Metabolic syndrome impairs physical function, health-related quality of life, and peripheral circulation in patients with intermittent claudication.
    Gardner AW; Montgomery PS; Parker DE
    J Vasc Surg; 2006 Jun; 43(6):1191-6; discussion 1197. PubMed ID: 16765237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [On the treatment of "intermittent claudication" in chronic peripheral obliterating arteriopathies of the lower extremities caused by arteriosclerosis and Buerger's disease].
    Seghezzi R; Pedroni G; Borri P
    Chir Ital; 1967; 19():Suppl 2:222+. PubMed ID: 5190600
    [No Abstract]   [Full Text] [Related]  

  • 37. The walking impairment questionnaire: an effective tool to assess the effect of treatment in patients with intermittent claudication.
    Nicolaï SP; Kruidenier LM; Rouwet EV; Graffius K; Prins MH; Teijink JA
    J Vasc Surg; 2009 Jul; 50(1):89-94. PubMed ID: 19563956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication.
    Nicolaï SP; Teijink JA; Prins MH;
    J Vasc Surg; 2010 Aug; 52(2):348-55. PubMed ID: 20478681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication.
    Mohler ER; Klugherz B; Goldman R; Kimmel SE; Wade M; Sehgal CM
    Vasc Med; 2000; 5(4):231-7. PubMed ID: 11213235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in patients with intermittent claudication using the World Health Organisation (WHO) questionnaire.
    Breek JC; Hamming JF; De Vries J; Aquarius AE; van Berge Henegouwen DP
    Eur J Vasc Endovasc Surg; 2001 Feb; 21(2):118-22. PubMed ID: 11237783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.